IMPACT OF DISEASE PROGRESSION ON PATIENT REPORTED OUTCOMES IN ADVANCED NSCLC: EVIDENCE FROM PATIENTS TREATED IN REAL WORLD COMMUNITY ONCOLOGY SETTINGS

被引：0
|
作者：
Walker, M. S. [1 ]
Wong, W. [2 ]
Ravelo, A. [2 ]
Hazard, S. [2 ]
Miller, P. J. [1 ]
Schwartzberg, L. [3 ]
机构：
[1] Vector Oncol, Memphis, TN USA
[2] Genentech Inc, South San Francisco, CA USA
[3] West Clin, Memphis, TN USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN147
引用
收藏
页码：A160 / A160
页数：1
相关论文
共 50 条
  • [1] Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings
    Walker, Mark S.
    Wong, William
    Ravelo, Arliene
    Miller, Paul J. E.
    Schwartzberg, Lee S.
    [J]. CLINICAL LUNG CANCER, 2018, 19 (02) : 139 - 147
  • [2] EFFECT OF BRAIN METASTASIS ON PATIENT-REPORTED OUTCOMES IN ADVANCED NSCLC TREATED IN REAL-WORLD COMMUNITY ONCOLOGY SETTINGS
    Walker, M. S.
    Wong, W.
    Ravelo, A.
    Miller, P. J.
    Schwartzberg, L.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A160 - A160
  • [3] Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study
    Mark S. Walker
    William Wong
    Arliene Ravelo
    Paul J. E. Miller
    Lee S. Schwartzberg
    [J]. Health and Quality of Life Outcomes, 15
  • [4] Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study
    Walker, Mark S.
    Wong, William
    Ravelo, Arliene
    Miller, Paul J. E.
    Schwartzberg, Lee S.
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2017, 15
  • [5] Prospective assessment of quality of life in patients with advanced NSCLC treated in real world community oncology settings: Effects of initial treatment regimen and disease progression.
    Walker, Mark S.
    Goertz, Hans-Peter
    Ravelo, Arliene
    Hazard, Sebastien
    Miller, Paul J. E.
    Schwartzberg, Lee Steven
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] EFECTIVENESS OUTCOMES IN PATIENTS WITH ADVANCED NSCLC TREATED IN REAL-WORLD COMMUNITY ONCOLOGY SETTINGS: RESULTS FROM A PROSPECTIVE MEDICAL RECORD REGISTRY STUDY
    Walker, M. S.
    Wong, W.
    Ravelo, A.
    Hazard, S.
    Miller, P. J.
    Schwartzberg, L.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A137 - A137
  • [7] TREATMENT PATTERNS AND BASELINE CHARACTERISTICS OF A PROSPECTIVE COHORT OF PATIENTS WITH ADVANCED NSCLC TREATED IN REAL WORLD COMMUNITY ONCOLOGY SETTINGS
    Walker, M. S.
    Ravelo, A.
    Miller, P. J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A101 - A102
  • [8] Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study
    Camou, Fabrice
    Lagadec, Audrey
    Coutinho, Angela
    Berger, Marc G.
    Cador-Rousseau, Berengere
    Gaches, Francis
    Belmatoug, Nadia
    [J]. MOLECULAR GENETICS AND METABOLISM, 2023, 140 (03)
  • [9] Real World Utilization and Outcomes of ALK-Positive Crizotinib Treated Metastatic NSCLC Patients in US Community Oncology Practice
    Reynolds, Craig
    Masters, Elizabeth
    Black-Shinn, Jenny
    Mardekian, Jack
    Espirito, Janet
    Boyd, Marley
    Chioda, Marc
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1172 - S1173
  • [10] COMMUNITY ONCOLOGY PERCEPTION AND PERSPECTIVES ON PATIENT REPORTED OUTCOMES (PROS) AND REAL-WORLD EVIDENCE (RWE) RESEARCH IN THE CONTEMPORARY ERA
    Nabhan, C.
    Braverman, J.
    Fillman, J.
    Ernst, F. R.
    Feinberg, B. A.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A136 - A136
12345